Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07344584

A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area

The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult males or non-pregnant, non-breastfeeding adult females.

  • Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face.
  • Intent to undergo treatment for correction of lines and wrinkles in the cheek region.
  • Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.).

Inclusion criteria

4-5 apply only to female participants of childbearing potential:

  • Agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment.
  • Negative UPT at the screening and baseline visits.

Exclusion criteria

  • Known/previous allergy or hypersensitivity.
  • Known/previous allergy or hypersensitivity to local anesthetics.
  • Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion.
  • Any previous aesthetic procedures or implants in the treatment area.
  • Presence of any disease or lesions in the treatment area.
  • An underlying known disease, a surgical or medical condition that would expose the participant to undue risk.
  • Use of concomitant medication that have the potential to prolong bleeding times.
  • Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol.
  • Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

Treatment and study plan

GP0122

Device

Injectable gel.

GP0124

Device

Injectable gel.

Primary outcomes

  1. Number of Participants With all Adverse Events (AEs)

    Time frame: From Day 1 up to last visit (Up to 12 months)

  2. Number of Participants With Post-Treatment Responses as Assessed Using Subject Diary Data

    Time frame: From Day 1 up to Day 28

  3. Participant's Pain Assessment Using Numeric Pain Scale (NPS) Immediately Post Treatment and 30 Minutes Post Treatment

    Time frame: Immediately and 30 minutes after each treatment

Secondary outcomes

  1. Responder Rates Based on the Treating Investigator's Live Assessment of the GCWS at Rest at Months 3, 6, 9 and 12

    Time frame: At Months 3, 6, 9 and 12

  2. Responder Rates Based on the Treating Investigator's Live Assessment of the CSQS-CL at Rest at Months 3, 6, 9 and 12

    Time frame: At Months 3, 6, 9 and 12

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Project Manager

CONTACT

[email protected]

8179615000 ext. +1

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.